

Insufficient Control of Blood Pressure and Incident Diabetes

RAFFAELE IZZO, MD, PHD¹
GIOVANNI DE SIMONE, MD²
MARCELLO CHINALI, MD, PHD²
GUIDO IACCARINO, MD, PHD¹
VALENTINA TRIMARCO, PHD³

FRANCESCO ROZZA, MD, PHD¹
RENATA GIUDICE, MD¹
BRUNO TRIMARCO, MD¹
NICOLA DE LUCA, MD¹

OBJECTIVE — Incidence of type 2 diabetes might be associated with preexisting hypertension. There is no information on whether incident diabetes is predicted by blood pressure control. We evaluated the hazard of diabetes in relation to blood pressure control in treated hypertensive patients.

RESEARCH DESIGN AND METHODS — Nondiabetic, otherwise healthy, hypertensive patients ($N = 1,754$, mean \pm SD age 52 ± 11 years, 43% women) participated in a network over 3.4 ± 1 years of follow-up. Blood pressure was considered uncontrolled if systolic was ≥ 140 mmHg and/or diastolic was ≥ 90 mmHg at the last outpatient visit. Diabetes was defined according to American Diabetes Association guidelines.

RESULTS — Uncontrolled blood pressure despite antihypertensive treatment was found in 712 patients (41%). At baseline, patients with uncontrolled blood pressure were slightly younger than patients with controlled blood pressure (51 ± 11 vs. 53 ± 12 years, $P < 0.001$), with no differences in sex distribution, BMI, duration of hypertension, baseline blood pressure, fasting glucose, serum creatinine and potassium, lipid profile, or prevalence of metabolic syndrome. During follow-up, 109 subjects developed diabetes. Incidence of diabetes was significantly higher in patients with uncontrolled (8%) than in those with controlled blood pressure (4%, odds ratio 2.08, $P < 0.0001$). In Cox regression analysis controlling for baseline systolic blood pressure and BMI, family history of diabetes, and physical activity, uncontrolled blood pressure doubled the risk of incident diabetes (hazard ratio [HR] 2.10, $P < 0.001$), independently of significant effects of age (HR 1.02 per year, $P = 0.03$) and baseline fasting glucose (HR 1.10 per mg/dl, $P < 0.001$).

CONCLUSIONS — In a large sample of treated nondiabetic hypertensive subjects, uncontrolled blood pressure is associated with twofold increased risk of incident diabetes independently of age, BMI, baseline blood pressure, or fasting glucose.

Diabetes Care 32:845–850, 2009

Arterial hypertension is common in patients with type 2 diabetes. A survey of over 1,500 patients with diabetes, conducted between 1988 and 1994, determined that 60–80% had blood pressure higher than 130/85 mmHg or had been prescribed antihypertensive medication (1). Results from MRFIT (Multiple Risk Factor Intervention

Trial) indicated that diabetes confers greater cardiovascular risk for comparable levels of other cardiovascular risk factors, suggesting that blood pressure control should be more rigorous in the presence of diabetes (2). However, there is no clearly defined temporal relationship between diabetes and hypertension. Incidence of type 2 diabetes, in fact,

also increases with increased baseline blood pressure in women without prevalent diabetes, based on modified blood pressure categories from the 2007 European Society of Hypertension/European Society of Cardiology (ESH/ESC) guidelines (3). There is increasing evidence of a substantial interplay of metabolic factors with arterial hypertension (4,5). We have recently shown that optimal control of blood pressure is blunted by coexisting metabolic risk factors, clustering the phenotype of metabolic syndrome (4). There is no information about whether suboptimal control of blood pressure might also be associated with incident diabetes, independently of confounders. Accordingly, we tested the hypothesis that insufficient control of blood pressure is an independent risk factor for diabetes in a cohort of hypertensive patients with initial normal fasting plasma glucose.

RESEARCH DESIGN AND METHODS

As previously reported (6), beginning in 1997 we generated a network, the Campania Salute Network, among the Hypertension Center of the Federico II University Hospital (Naples, Italy), 23 community hospital-based hypertension clinics, and 60 general practitioners from our district area, including over 12,000 cardiovascular patients, of whom 10,254 had arterial hypertension. Among hypertensive subjects, 7,422 were initially free of prevalent cardiovascular disease (6). Prevalent cardiovascular disease was defined at each patient's first examination in our outpatient clinic, and criteria included previous myocardial infarction, angina, or procedures of coronary revascularization; stroke or transient ischemic attack; or congestive heart failure. Prevalent cardiovascular disease was excluded by the Committee for Event Adjudication in the Hypertension Center and was based on patient history, contact with the reference general practitioner, and clinical records documenting occurrence of disease.

Criteria for selection in the present study included the availability of follow-up data for at least 2 years and absence of diabetes at the time of the first visit. According to these criteria, we excluded 5,668 patients: 4,957 with < 2

From the ¹Department of Clinical Medicine, Cardiovascular, and Immunological Sciences, Federico II University–Naples, Naples, Italy; the ²Department of Clinical and Experimental Medicine, Federico II University–Naples, Naples, Italy; and the ³Department of Neuroscience, Federico II University–Naples, Naples, Italy.

Corresponding author: Bruno Trimarco, trimarco@unina.it.

Received 23 October 2008 and accepted 3 February 2009.

Published ahead of print at <http://care.diabetesjournals.org> on 17 February 2009. DOI: 10.2337/dc08-1881.

© 2009 by the American Diabetes Association. Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. See <http://creativecommons.org/licenses/by-nc-nd/3.0/> for details.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

years of follow-up (3,258 due to enrollment in the past 2 years and 1,699 lost to follow-up), 386 with prevalent diabetes, and 325 with reported impaired fasting glucose at the time of the first visit. Thus, we analyzed 1,754 Caucasian hypertensive patients (43% women mean \pm SD age 52 ± 11 years) with normal fasting glucose who had been followed up for 3.5 ± 1.8 years. All eligible participants underwent at least two control visits after the first examination.

The database generation of the Campania Salute Network was approved by the Federico II University Hospital Ethic Committee. Signed informed consent for the possibility of using data for scientific purposes was obtained.

Laboratory tests and definitions

Fasting plasma glucose and lipid profiles were measured by standard methods. Glomerular filtration rate (GFR) was estimated from serum creatinine by the modified MDRD (Modification of Diet in Renal Disease) equation (7).

According to a questionnaire, patients were asked to classify their lifestyle as sedentary or nonsedentary. This information was used in the analysis as a raw indicator of physical activity.

Systolic and diastolic blood pressure was measured at each visit by a standard sphygmomanometer after patients had been in a sitting position for 5 min, according to ESH/ESC guidelines (8). For each patient, three blood pressure measurements were obtained at 2-min intervals while the patient was in the sitting position. The average of these measurements was used for the analysis (8).

BMI was calculated at each visit; patients with values ≥ 30 kg/m² were classified as obese and were assumed to have central fat distribution (9). Diagnosis of metabolic syndrome was, therefore, issued according to modified Adult Treatment Panel (ATP)-III criteria (4,5) and required at least two of the following metabolic risk factors: plasma triglycerides ≥ 150 mg/dl, fasting plasma glucose ≥ 110 mg/dl, HDL cholesterol ≤ 40 mg/dl for men or ≤ 50 mg/dl for women, and BMI ≥ 30 kg/m² (as a surrogate of increased waist girth). Non-HDL cholesterol was also determined and was calculated as the difference between total and HDL cholesterol.

The number of antihypertensive medications used at the time of each visit was also evaluated. Blood pressure was considered controlled at $< 140/90$ mmHg

and otherwise considered uncontrolled. Reported medical diagnostic codes for diabetes and prescriptions of oral hypoglycemic drugs or insulin were used to identify prevalent and incident cases of diabetes. Prevalent and incident diabetes was diagnosed when fasting plasma glucose was > 125 mg/dl, according to American Diabetes Association guidelines (10).

Statistical analysis

Data were analyzed using SPSS (version 12.0; SPSS, Chicago, IL) and expressed as means \pm 1 SD. All variables deviating from normal distribution were log transformed before parametric statistics were calculated. Descriptive statistics were performed using ANOVA or χ^2 distribution, with Monte Carlo simulation to generate exact *P* values.

The last available blood pressure value was used to classify controlled and uncontrolled patients. For patients developing diabetes, we used the last available controlled blood pressure value before diabetes was diagnosed. Incidence of diabetes in relation to controlled or uncontrolled blood pressure was evaluated using Cox regression, by the enter procedure, controlling for baseline values of age, sex, BMI, fasting plasma glucose, family history of diabetes, blood pressure at the time of the first visit, and sedentary or nonsedentary lifestyle. Alternative models were also computed using the last available blood pressure value instead of categories of controlled/uncontrolled blood pressure.

To account for therapy in the Cox model, single classes of medications, including anti-renin-angiotensin system (RAS) drugs (ACE inhibitors and/or AT1 receptor antagonists), calcium-channel blockers (CCBs), β -blockers, and thiazide diuretics, were dichotomized according to their overall use during the individual follow-up, based on the frequency of prescription during the control visits. Thus, all medications used for more than 50% of control visits were considered as covariates in a new proportional hazards analysis. In this Cox model, we used a hierarchical model with a 1st step in which all covariates used in the previous Cox analysis were entered by a backward model-building procedure (*P* to enter < 0.05 and *P* to remove ≥ 0.15) and a 2nd step in which the classes of medications were thereafter forced into the model.

RESULTS— Uncontrolled blood pressure despite therapy was found in 712 patients (41% of population). Baseline characteristics in relation to control of blood pressure are shown in Table 1. At baseline, patients with subsequent uncontrolled blood pressure were younger ($P < 0.001$) and had a higher heart rate ($P < 0.02$) than patients with controlled blood pressure, with no differences in sex distribution, BMI, reported duration of hypertension, baseline blood pressure values, metabolic profile (glucose, uric acid, and lipids), serum creatinine and electrolytes, GFR, or prevalence of metabolic syndrome. Uncontrolled blood pressure was also associated with a slightly reduced number of control visits over the follow-up period ($P = 0.05$).

During follow-up, 109 patients (6% of the population, 41% women) developed diabetes. At baseline, patients with subsequent diabetes were older (56.2 ± 9.7 vs. 51.6 ± 11.6 years) and had greater BMI (29.2 ± 4 vs. 27.3 ± 4 kg/m²), fasting glucose (107.9 ± 10 vs. 92.5 ± 11.6 mg/dl), uric acid (5.7 ± 1.8 vs. 5.0 ± 1.5 mg/dl), plasma triglycerides (169.4 ± 112.7 vs. 126.5 ± 68.4 mg/dl), and prevalence of metabolic syndrome (60.7 vs. 21.4%) than patients without incident diabetes (all $P < 0.001$). In univariate cross-tabulation, incident diabetes was 35% less in nonsedentary than in sedentary participants (odds ratio [OR] 0.65 [95% CI 0.44–0.97], $P = 0.041$). Reported duration of hypertension was also longer (8.7 ± 7.5 vs. 6.8 ± 6.7 years, $P = 0.013$), and family history of diabetes was more frequent (8.2 vs. 5.1%, $P = 0.017$). In univariate cross-tabulation, incident diabetes was 2.45-fold higher in participants with BMI ≥ 30 kg/m² (2.45 [1.62–3.71], $P < 0.0001$). No differences were found in sex distribution, number of visits per year, baseline blood pressure and heart rate, serum creatinine and electrolytes, GFR, total cholesterol, HDL cholesterol, and uric acid. There was no significant variation of BMI over time in either group.

Prediction of incident diabetes and blood pressure control

Risk of incident diabetes was significantly higher in patients with uncontrolled (8%) than in those with controlled blood pressure (4%, OR 2.08, $P < 0.0001$). In Cox analysis controlling for age at the time of the first visit, sex, baseline values of systolic blood pressure, family history of diabetes, fasting glucose, BMI, and reported




Figure 1—Cumulative hazard of incident diabetes in nondiabetic hypertensive patients under antihypertensive therapy in relation to blood pressure control, after adjusting for age, sex, systolic blood pressure, family history of diabetes, BMI, and plasma glucose at baseline (see text for explanation).

physical activity, incident diabetes remained more than twofold higher in patients with uncontrolled than in those with controlled blood pressure (hazard ratio [HR] 2.1 [95% CI 1.41–3.12], $P < 0.0003$), with additional significant effects for higher baseline fasting glucose (1.1 [1.08–1.13], $P < 0.0001$) and older age (1.02 [1.00–1.04], $P < 0.03$) and no detectable effect for the other covariates (Fig. 1). Wald statistics suggest that fasting plasma glucose was the strongest predictor of incident diabetes and that suboptimal control of blood pressure was the second strongest predictor.

Alternative Cox models were generated using blood pressure as a continuous variable rather than dichotomizing it into controlled and uncontrolled. In these alternative models, both systolic (not diastolic) blood pressure (HR 1.02 per mmHg [95% CI 1.01–1.03], $P < 0.01$) and mean blood pressure (1.03 per mmHg [1.01–1.06], $P < 0.01$) were significant, independent predictors of incident diabetes.

In another Cox model, using the modified ATP-III definition of metabolic syndrome instead of fasting plasma glucose and BMI, together with the risk

of incident diabetes associated with metabolic syndrome (HR 4.4 [95% CI 2.9–6.7]), uncontrolled blood pressure maintained or even increased its predictive value (2.7 [1.7–4.1], both $P < 0.0001$).

Antihypertensive therapy

During follow-up, slightly more antihypertensive medications were prescribed in patients with controlled than in those with uncontrolled blood pressure (1.57 ± 0.94 vs. 1.47 ± 0.90 drugs, $P < 0.03$). Single classes of antihypertensive medications were, therefore, examined in relation to incident diabetes, and the frequency of use over the entire follow-up time in censored and uncensored observations was considered. We arbitrarily evaluated medications prescribed in more than 50% of available visits. Because of potential pharmacological interaction favoring development of diabetes, the association between thiazides and β -blockers was also specifically examined. Thus, the classes of antihypertensive medications analyzed were thiazides, β -blockers, anti-RAS drugs, CCBs, and combinations of thiazides and β -blockers.

The frequency of prescription of β -blockers was twofold higher in patients with incident diabetes than in those without incident diabetes (HR 2.04 [95% CI 1.36–3.07], $P < 0.0008$). Similarly, combinations of thiazides and β -blockers were threefold more frequent in patients with than in those without incident diabetes (3.00 [1.72–5.26], $P < 0.0002$). There was no difference in prescriptions for thiazides without β -blockers, anti-RAS drugs, or CCBs. Another Cox model was, therefore, generated including classes of antihypertensive medications in addition to the covariates used in the previous Cox model. Table 2 shows that uncontrolled blood pressure retained a nearly twofold higher probability of association with incident diabetes, independently of all covariates, including treatment. In this model, additional significant predictors were older age, higher baseline fasting glucose, higher BMI, and therapy with β -blockers (Table 2).

CONCLUSIONS — In this study, for the first time we demonstrate that suboptimal control of blood pressure is a strong predictor of incident type 2 diabetes in initially normoglycemic, hypertensive in-

Table 1—Demographic, clinical, and laboratory characteristics of the study population

	Controlled blood pressure	Uncontrolled blood pressure	P ≤
n	1,042	712	
Age (years)	52.7 ± 11.6	50.6 ± 11.3	0.0001
Sex (%M/F)	58/42	56/44	NS
BMI (kg/m ²)	27.3 ± 3.9	27.6 ± 4.1	NS
Reported duration of hypertension (years)	7.2 ± 7.1	6.5 ± 6.3	NS
Visits per year (n)	2.34 ± 1.03	2.25 ± 1.02	0.047
Systolic blood pressure (mmHg)	159.8 ± 21.8	158.0 ± 19.2	NS
Diastolic blood pressure (mmHg)	99.6 ± 10.8	99.6 ± 10.2	NS
Heart rate (bpm)	71.87 ± 11.29	73.16 ± 12.58	0.028
Fasting glucose (mg/dl)	93.5 ± 12.2	93.2 ± 12.0	NS
Uric acid (mg/dl)	5.1 ± 1.4	5.1 ± 1.7	NS
Blood urea nitrogen (mg/dl)	37.6 ± 10.1	36.3 ± 11.8	NS
Serum creatinine (mg/dl)	0.94 ± 0.2	0.93 ± 0.2	NS
GFR (ml/min)	82.7 ± 19.9	83.7 ± 19.1	NS
K ⁺ (mEq/l)	4.4 ± 0.4	4.4 ± 0.4	NS
Na ⁺ (mEq/l)	141.2 ± 3.3	141.3 ± 3.1	NS
Cholesterol (mg/dl)	206.5 ± 38.6	207.2 ± 37.4	NS
HDL cholesterol (mg/dl)	50.2 ± 12.3	50.7 ± 12.7	NS
Non-HDL cholesterolemia (mg/dl)	156.5 ± 37.9	156.7 ± 37.7	NS
Triglycerides (mg/dl)	129.2 ± 67.7	128.8 ± 79.0	NS
Metabolic syndrome (%)	24.2	23.6	NS

Data are means ± SD or percentage of the relevant group of patients. NS, not significant.

dividuals after a follow-up of at least 2 years on antihypertensive treatment. This effect is independent of age, baseline fasting glucose, presence of metabolic syndrome, and type of antihypertensive therapy. Prescription of β-blockers, but not of thiazides, is also strongly and independently associated with new onset of diabetes.

Our findings extend previous observations indicating that incident type 2 diabetes is more frequent in hypertensive than in normotensive subjects (3,11). In particular, Conen et al. (3) recently reported a clear correlation between higher incidence of type 2 diabetes and blood pressure levels in a large population of

women, based on modified categories from the 2007 ESH/ESC guidelines.

The relation between suboptimal control of blood pressure and incident diabetes also paralleled evidence of different follow-up profiles in censored and uncensored individuals. Patients with incident diabetes underwent fewer visits each year, were prescribed fewer medications, and presented with a larger BMI. It is possible that a less attentive adherence to the suggestions of the specialist both in terms of compliance to the treatment and changes in lifestyle could be at least in part associated with the increased risk of developing diabetes. However, this possibility was partly contradicted by our pre-

vious demonstration that the phenotype of metabolic syndrome, a potent risk factor for diabetes in our analysis also, is associated with a high likelihood of uncontrolled blood pressure, despite the greater number of prescribed medications.

The other interesting aspect emerging from our analysis is the evidence of the independent relation of β-blocker therapy to the incidence of diabetes, which was consistent with recent literature (12). In contrast, diuretic therapy did not independently predict diabetes, a finding that was inconsistent with some (13) but not all studies (11,14). Gress et al. (11) have shown no significant, independent effect of thiazides in their population-based study once demographic, environmental, and metabolic cofactors were taken into account. In the ALLHAT (Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial) study, other than adjustment for chlorthalidone and increased risk of diabetes after 2 and 4 years (14), no multivariate adjustment comparable with that used in the model of the present study was attempted to verify whether this effect was independent of confounders. In addition, whereas in the ALLHAT study design diuretic therapy was not associated with any anti-RAS medication (and in fact K⁺ levels were significantly lower in the group on diuretics), in all analyzed patients in the present study thiazides were associated with other medications and K⁺ levels were indistinguishable between the groups. Another characteristic to consider in our population is that thiazides were used at very low doses. There is some evidence that thiazides may also produce or increase hepatic insulin resistance, but this effect is dose dependent and associated with hypokalemia (15).

The two main findings in our study (i.e., regarding the relation of uncontrolled blood pressure and use of β-blockers to incident diabetes) are biologically plausible and in accord with most recent findings suggesting that microvascular alterations might precede development of diabetes (16). Because the goal of our study was to assess the risk of incident diabetes in poorly controlled hypertensive patients, independent of therapeutic aggressiveness (and therefore including patients with possible suboptimal therapy at the time of censoring), these findings suggest that the timing of achieving target blood pressure values might also be substantially relevant to preventing diabetes,

Table 2—Hazard of incident diabetes in nondiabetic, treated hypertensive patients, including classes of antihypertensive medications

	B	Wald	P ≤	HR	95.0% CI	
					Lower	Upper
Fasting glucose (mg/dl)					1.07	1.12
BMI (kg/m ²)	0.03	7.09	0.01	1.08	1.02	1.14
Age (years)	0.03	6.33	0.014	1.03	1.01	1.05
Sex (M/F)	0.03	0.02	0.9	1.03	0.67	1.60
Thiazide diuretics	−0.28	1.73	0.21	0.75	0.48	1.18
β-Blockers	0.77	13.05	0.0001	2.17	1.41	3.34
Anti-RAS drugs	0.12	0.19	0.65	1.12	0.68	1.86
Suboptimal blood pressure control	0.63	7.58	0.004	1.88	1.23	2.88

a possibility that should be tested in ad hoc clinical trials.

The temporal sequence observed in our study suggests some possibilities to be explored in future research. First, both hypertension and diabetes might share a common abnormality of microvascular function that might be corrected by anti-hypertensive therapy. When generalized, dysfunction is more easily detectable with increased blood pressure than with metabolic alterations preceding diabetes, which provides an explanation for hypertension appearing before diabetes. This hypothesis is supported by increasing evidence that microvascular dysfunction might be the background abnormality in experimental diabetes (17). However, although vascular rarefaction has been generally suggested to contribute to insulin resistance (17), a cause-and-effect relationship has not been demonstrated. Another possibility is that the lack of effective control of blood pressure parallels persistent neurohormonal abnormalities, including potential defects in the sympathetic system (18) and/or RAS activity (19), which in the long run participate in the precipitation of diabetes.

The unfavorable metabolic consequence of β -blockade is likely due to decreased insulin sensitivity, which is also demonstrated in hypertensive patients (20), associated with insulin-related metabolic features (21) and deleterious effects on insulin secretion (22). As widely reported, insulin resistance evolves into diabetes once β -cell failure occurs (23). In addition to this mechanism, β -receptor blockade might favor enhancement of hepatic glucose output, which has been demonstrated in rats but not humans (24).

A potential limitation of this study is the absence of direct information on body fat distribution. Because of this limitation, in addition to our use of BMI as a continuous variable, we used a cut point of BMI to categorize obesity. The cut point of BMI for obesity has been previously used as a surrogate of waist girth in studies on metabolic syndrome, and the International Diabetes Federation indicates that when BMI is in the range of obesity, a central fat distribution can be assumed. In addition, at least in terms of prediction of diabetes, BMI has been shown to be as informative as waist circumference, waist-to-hip ratio, or direct visceral fat measured by computed tomography (25). Finally, the prevalence of obesity in this population is likely affected by our initial selection, which excluded subjects with type 2 dia-

betes or impaired fasting glucose at baseline examination.

Another potential limitation of this study is the unavailability of information regarding albuminuria because the data collection was initiated at a time when albuminuria was not yet required as a primary workup test in all outpatients. According to selection criteria in the present study, we included relatively healthy patients who did not require assessment of albuminuria.

Acknowledgments—No potential conflicts of interest relevant to this article were reported.

References

- Geiss LS, Rolka DB, Engelgau MM. Elevated blood pressure among U.S. adults with diabetes, 1988–1994. *Am J Prev Med* 2002;22:42–48
- Stamler J, Vaccaro O, Neaton JD, Wentworth D. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. *Diabetes Care* 1993;16:434–444
- Conen D, Ridker PM, Mora S, Buring JE, Glynn RJ. Blood pressure and risk of developing type 2 diabetes mellitus: the Women's Health Study. *Eur Heart J* 2007;28:2937–2943
- Arcucci O, de Simone G, Izzo R, Rozza F, Chinali M, Rao MA, Bodenizza C, De Luca N, Trimarco B. Association of suboptimal blood pressure control with body size and metabolic abnormalities. *J Hypertens* 2007;25:2296–2300
- de Simone G, Olsen MH, Wachtell K, Hille DA, Dahlof B, Ibsen H, Kjeldsen SE, Lyle PA, Devereux RB. Clusters of metabolic risk factors predict cardiovascular events in hypertension with target-organ damage: the LIFE study. *J Hum Hypertens* 2007;21:625–632
- De Luca N, Izzo R, Iaccarino G, Malini PL, Morisco C, Rozza F, Iovino GL, Rao MA, Bodenizza C, Lanni F, Guerrero L, Arcucci O, Trimarco B. The use of a telematic connection for the follow-up of hypertensive patients improves the cardiovascular prognosis. *J Hypertens* 2005;23:1417–1423
- Hallan S, Asberg A, Lindberg M, Johnsen H. Validation of the Modification of Diet in Renal Disease formula for estimating GFR with special emphasis on calibration of the serum creatinine assay. *Am J Kidney Dis* 2004;44:84–93
- Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, Grassi G, Heagerty AM, Kjeldsen SE, Laurent S, Narkiewicz K, Ruilope L, Rynkiewicz A, Schmieder RE, Boudier HA, Zanchetti A, Vahanian A, Camm J, De Caterina R, Dean V, Dickstein K, Filippatos G, Funck-Brentano C, Hellemans I, Kristensen SD, McGregor K, Sechtem U, Silber S, Tendera M, Widimsky P, Zamorano JL, Erdine S, Kiowski W, Agabiti-Rosei E, Ambrosioni E, Lindholm LH, Viigimaa M, Adamopoulos S, Agabiti-Rosei E, Ambrosioni E, Bertomeu V, Clement D, Erdine S, Farsang C, Gaita D, Lip G, Mallion JM, Manolis AJ, Nilsson PM, O'Brien E, Ponikowski P, Redon J, Ruschitzka F, Tamarago J, van Zwieten P, Waeber B, Williams B. 2007 guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). *J Hypertens* 2007;25:1105–1187
- Alberti KG, Zimmet P, Shaw J. The metabolic syndrome: a new worldwide definition. *Lancet* 2005;366:1059–1062
- Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. *Diabetes Care* 1997;20:1183–1197
- Gress TW, Nieto FJ, Shahar E, Wofford MR, Brancati FL. Hypertension and anti-hypertensive therapy as risk factors for type 2 diabetes mellitus. *N Engl J Med* 2000;342:905–912
- Almgren T, Wilhelmsen L, Samuelsson O, Himmelmann A, Rosengren A, Andersson OK. Diabetes in treated hypertension is common and carries a high cardiovascular risk: results from a 28-year follow-up. *J Hypertens* 2007;25:1311–1317
- Verdecchia P, Angeli F, Reboldi G. New-onset diabetes, antihypertensive treatment, and outcome. *Hypertension* 2007;50:459–460
- Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). *JAMA* 2002;288:2981–2997
- Harper R, Ennis CN, Heaney AP, Sheridan B, Gormley M, Atkinson AB, Johnston GD, Bell PM. A comparison of the effects of low- and conventional-dose thiazide diuretic on insulin action in hypertensive patients with NIDDM. *Diabetologia* 1995;38:853–859
- Nguyen TT, Wang JJ, Islam FM, Mitchell P, Tapp RJ, Zimmet PZ, Simpson R, Shaw J, Wong TY. Retinal arteriolar narrowing predicts incidence of diabetes: the Australian Diabetes, Obesity and Lifestyle (AusDiab) Study. *Diabetes* 2008;57:536–539
- Anneren C, Welsh M, Jansson L. Glucose intolerance and reduced islet blood flow in transgenic mice expressing the FRK tyrosine kinase under the control of the rat insulin promoter. *Am J Physiol Endocrinol Metab* 2007;292:E1183–E1190

18. Lembo G, Napoli R, Capaldo B, Rendina V, Iaccarino G, Volpe M, Trimarco B, Sacca L. Abnormal sympathetic overactivity evoked by insulin in the skeletal muscle of patients with essential hypertension. *J Clin Invest* 1992;90:24–29
19. Ogihara T, Asano T, Ando K, Chiba Y, Sakoda H, Anai M, Shojima N, Ono H, Onishi Y, Fujishiro M, Katagiri H, Fukushima Y, Kikuchi M, Noguchi N, Aburatani H, Komuro I, Fujita T. Angiotensin II-induced insulin resistance is associated with enhanced insulin signaling. *Hypertension* 2002;40:872–879
20. Bakris GL, Fonseca V, Katholi RE, McGill JB, Messerli FH, Phillips RA, Raskin P, Wright JT Jr, Oakes R, Lukas MA, Anderson KM, Bell DS. Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial. *JAMA* 2004;292:2227–2236
21. Iaccarino G, Trimarco V, Lanni F, Cipolletta E, Izzo R, Arcucci O, De Luca N, Di Renzo G. β -Blockade and increased dyslipidemia in patients bearing Glu27 variant of β_2 adrenergic receptor gene. *Pharmacogenomics J* 2005;5:292–297
22. Struthers AD, Murphy MB, Dollery CT. Glucose tolerance during antihypertensive therapy in patients with diabetes mellitus. *Hypertension* 1985;7:1195–11101
23. Ferrannini E, Gastaldelli A, Miyazaki Y, Matsuda M, Mari A, DeFronzo RA. β -Cell function in subjects spanning the range from normal glucose tolerance to overt diabetes: a new analysis. *J Clin Endocrinol Metab* 2005;90:493–500
24. Sarafidis PA, Bakris GL. Antihypertensive treatment with beta-blockers and the spectrum of glycaemic control. *QJM* 2006;99:431–436
25. Bray GA, Jablonski KA, Fujimoto WY, Barrett-Connor E, Haffner S, Hanson RL, Hill JO, Hubbard V, Kriska A, Stamm E, Pi-Sunyer FX. Relation of central adiposity and body mass index to the development of diabetes in the Diabetes Prevention Program. *Am J Clin Nutr* 2008;87:1212–1218